EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ersodetug for refractory hypoglycemia due to malignant insulin-secreting tumors

Jonathan Strosberg, Sean M Brown, Shagufta Shaheen, Marilyn Tan, Jairo Arturo Noreña, Armen I Yerevanian, Linda Lester, Leah M Wilson, Ole-Petter R Hamnvik iD, Johannes Hofland iD, Jasmine K Sidhu, Gopal Saha und 4 weitere

The Journal of Clinical Endocrinology & Metabolism · 2026

DOI: 10.1210/clinem/dgag318 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Jonathan Strosberg und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA. Hauptthemen laut MEDLINE: Hypoglycemia, Insulinoma, Pancreatic Neoplasms, Hyperinsulinism. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Rezolute, Inc. (Redwood City, CA, USA), Joslin Diabetes Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Refractory hypoglycemia is common in malignant insulin-secreting tumors and is associated with substantial morbidity. Ersodetug is a fully human monoclonal antibody that allosterically attenuates insulin receptor signaling with the potential to treat various forms of hyperinsulinism (HI). We retrospectively report outcomes from compassionate use of ersodetug in 8 individuals with refractory hypoglycemia due to tumor HI.

Methods

Ersodetug was administered intravenously at 6 or 9 mg/kg every 1-2 weeks initially, followed by a frequency of every 2-5 weeks, as appropriate. Glycemic, functional, and safety outcomes were analyzed.

Results

Eight adults (4M/4F; 24-74 years; Eastern Cooperative Oncology Group [ECOG] 1-3) received ersodetug for insulin-secreting tumors (metastatic insulinoma, n = 7; cervical neuroendocrine carcinoma, n = 1). No drug-related serious adverse events were observed. Most patients experienced improved glycemic control, including discontinuation of parenteral glucose in 6 of the 7 applicable patients (median, 4.5 days) and a 35.6% relative reduction from baseline in time in hypoglycemia (<70 mg/dL) by continuous glucose monitoring (mean 12.4-8.0%; pseudo-median paired change of -3.8 percentage points [90% CI, −8.2 to −1.1]; P = .02). These glycemic improvements permitted hospital discharge and reductions in other antihypoglycemic therapies beyond glucose infusion rate (pseudo-median change, −2.5; 90% CI, −3.5 to −1.0; P = .02), with associated improvements in ECOG status. The median treatment duration with ersodetug (11.5 months, range 5-17) tended to correspond to patient lifespan in the setting of metastatic disease.

Conclusion

Ersodetug therapy resulted in reduced hypoglycemia burden, ability to discontinue parenteral glucose infusion, allowing discharge from hospital, use of fewer antihypoglycemic therapies, and improved ECOG performance status in individuals with severe, refractory tumor HI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypoglycemiaInsulinomaPancreatic NeoplasmsHyperinsulinismAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedHumansFemaleMiddle AgedAdultAgedMaleRetrospective StudiesYoung AdultCompassionate Use TrialsBlood GlucoseTreatment Outcome

Stichwörter der Autor:innen

ersodetuginsulin receptorinsulinomamonoclonal antibodyparaneoplastic hypoglycemiatumor hyperinsulinism

Substanzen

Blood GlucoseAntibodies, MonoclonalAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA.
  • Research Division, Joslin Diabetes Center (Harvard Medical School), Boston, MA 02115, USA.
  • Division of Endocrinology, Stanford University Medical Center, Stanford, CA 94305, USA.
  • Diabetes Unit, Massachusetts General Hospital (Harvard Medical School), Boston, MA 02114, USA.
  • Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health & Science University, Portland, OR 97239, USA.
  • Division of Endocrinology, Diabetes, and Metabolism, Brigham and Women's Hospital (Harvard Medical School), Boston, MA 02115, USA.

ORCID-Profile: Ole-Petter R Hamnvik, Johannes Hofland, Davelyn E Hood, Jonathan M Dreyfuss, Mary-Elizabeth Patti

Förderung

  • Rezolute, Inc. (Redwood City, CA, USA)
  • Joslin Diabetes Center

Zitieren

APA

Strosberg, J., Brown, S. M., Shaheen, S., Tan, M., Noreña, J. A., Yerevanian, A. I., Lester, L., Wilson, L. M., Hamnvik, O. R., Hofland, J., Sidhu, J. K., Saha, G., Hood, D. E., Roberts, B. K., Dreyfuss, J. M., & Patti, M. E. (2026). Ersodetug for refractory hypoglycemia due to malignant insulin-secreting tumors. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag318

Vancouver

Strosberg J, Brown SM, Shaheen S, Tan M, Noreña JA, Yerevanian AI, et al. Ersodetug for refractory hypoglycemia due to malignant insulin-secreting tumors. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgag318

BibTeX
@article{Strosberg2026,
  author = {Strosberg, Jonathan and Brown, Sean M and Shaheen, Shagufta and Tan, Marilyn and Noreña, Jairo Arturo and Yerevanian, Armen I and Lester, Linda and Wilson, Leah M and Hamnvik, Ole-Petter R and Hofland, Johannes and Sidhu, Jasmine K and Saha, Gopal and Hood, Davelyn E and Roberts, Brian K and Dreyfuss, Jonathan M and Patti, Mary-Elizabeth},
  title = {Ersodetug for refractory hypoglycemia due to malignant insulin-secreting tumors},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  doi = {10.1210/clinem/dgag318}
}
Kostenlos starten →